The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

New data show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.

Eli Lilly product development senior vice-president Jeff Emmick said: “Once weekly insulins like efsitora have the potential ...

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as ...

Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly ...

Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.

Combination may offer a substitute to basal-bolus insulin in people with type 2 diabetes inadequately controlled with daily basal insulin.

Eli Lilly said a once-weekly dose of insulin efsitora proved to reduce hemoglobin A1C in a Qwint-2 Phase 3 trial when compared with a daily dose of insulin in people with type 2 diabetes using insulin ...